The European Blood and Marrow Transplantation Textbook for Nurses : : Under the Auspices of EBMT.

The European Blood and Marrow Transplantation Textbook for Nurses : : Under the Auspices of EBMT.

Show other versions (2)
Saved in:
Bibliographic Details
:
Kenyon, Michelle.
TeilnehmendeR:
Babic, Aleksandra.
Place / Publishing House:Cham : : Springer International Publishing AG,, 2018.
©2018.
Year of Publication:2018
Edition:1st ed.
Language:English
Online Access:
Physical Description:1 online resource (318 pages)
Tags: Add Tag
No Tags, Be the first to tag this record!
Table of Contents:
  • Intro
  • Foreword
  • Preface
  • Contents
  • About the Author
  • Brief History of HSCT Nursing: HSCT Nursing Through the Ages and Its Evolution
  • Literature
  • 1: JACIE and Quality Management in HSCT: Implications for Nursing
  • 1.1 Background to JACIE
  • 1.2 Preparing for JACIE Accreditation
  • 1.2.1 Considerations
  • 1.2.2 Implementing a Quality Management System
  • 1.3 The JACIE Accreditation Process
  • 1.3.1 Start Working with the Standards
  • 1.3.2 Application for JACIE Accreditation
  • 1.3.3 Arranging the Inspection Date
  • 1.3.4 The Inspection
  • 1.3.5 The Inspection Report
  • 1.3.6 Corrections and Accreditation Award
  • 1.3.7 Post JACIE Accreditation
  • 1.4 JACIE Standards that Affect Nursing: Clinical and Collection
  • 1.4.1 Staffing and Nursing (Table 1.2)
  • 1.4.2 Training and Competencies (Tables 1.2 and 1.3)
  • 1.4.3 Benefits of Quality Management (Table 1.3)
  • 1.4.4 Audits (Table 1.3)
  • 1.4.5 Reporting Adverse Events (Table 1.3)
  • 1.4.6 Tracking of Collected Products (Table 1.3)
  • 1.4.7 Common Deficiencies: 5th Edition of the JACIE Standards
  • 1.5 JACIE: Implications on Nursing - The Nurse's Perspective
  • 1.5.1 Results of the Survey
  • 1.6 Results
  • 1.7 Does the JACIE Process Have Any Implications for Nurses?
  • 1.7.1 Implications: Staff Nurse's/Junior Nurse's Point of View
  • 1.7.2 Implications: Ward Manager's Point of View Can Be Summarised as Follows
  • 1.7.3 Implications: Clinical Nurse Specialist's Point of View Can Be Summarised as Follows
  • 1.7.4 Implications: Quality Manager's Point of View Can Be Summarised as Follows
  • 1.7.5 Implications: Nurse Coordinator's Point of View Can Be Summarised as Follows
  • 1.8 Conclusion of the Survey
  • 1.9 Discussion Points
  • Appendix 1.1. Citations Classified in the Role of the Nurse
  • References
  • 2: HSCT: How Does It Work?.
  • 2.1 What Nurses Need to Know
  • 2.1.1 Introduction
  • 2.1.2 Aims of HSCT
  • 2.1.3 Outcomes
  • 2.1.4 Nursing Considerations
  • 2.2 Different Types of HSCT
  • 2.2.1 Autologous Haematopoietic Stem Cell Transplantation
  • 2.2.2 Allogeneic Stem Cell Transplantation
  • 2.2.2.1 Allogeneic Transplantation from HLA-Matched Related Donor (MRD)
  • 2.2.2.2 Allogeneic from Unrelated Donor (MUD, MMUD)
  • 2.2.2.3 Cord Blood Transplantation
  • 2.2.2.4 Haploidentical Transplantation
  • 2.2.2.5 Syngeneic Transplantation
  • 2.3 The Stem Cell Sources
  • 2.3.1 Peripheral Blood Stem Cells
  • 2.3.2 Bone Marrow
  • 2.3.3 Umbilical Cord Blood
  • 2.3.4 HSCT Phases
  • 2.3.4.1 Neutropenic Phase
  • 2.4 Indications for Transplant in Malignant Disease
  • 2.4.1 Indications for Allogeneic HSCT
  • 2.4.2 Indications for Autologous HSCT
  • 2.5 Indications for Transplant in Non-malignant Diseases in Children
  • 2.5.1 Transplant in Primary Immunodeficiencies
  • 2.5.2 Severe Combined Immunodeficiencies
  • 2.5.3 Non-SCID Primary Immunodeficiencies
  • 2.5.4 Newborn Screening
  • 2.5.5 Inherited Bone Marrow Failure
  • 2.5.6 Inherited Diseases: Inborn Errors of Metabolism
  • References
  • References for Indications for Transplant in Non-malignant Diseases in Children
  • 3: Donor Selection
  • 3.1 Introduction
  • 3.2 Human Leukocyte Antigens
  • 3.3 Eligibility for HLA Typing of Potential Related Donors
  • 3.4 Algorithm of Donor Choice and Selection
  • 3.4.1 Donor Selection
  • 3.4.2 HLA Match
  • 3.4.3 Cytomegalovirus (CMV) Status
  • 3.4.4 Blood Group
  • 3.4.5 Sex Match
  • 3.4.6 Parity
  • 3.4.7 Age
  • 3.4.8 Donor Evaluation
  • 3.5 Special Considerations
  • 3.5.1 Screening of Elderly Donors
  • 3.5.2 Screening of Paediatric Donors
  • 3.5.3 Confidentiality
  • 3.5.4 Donor Consent and Clearance
  • 3.5.5 Stem Cell Source
  • References.
  • 4: Transplant Preparation
  • 4.1 The Role of Transplant Coordinator
  • 4.2 Information and Consent
  • 4.3 Information and Consents in the Paediatric Population
  • 4.4 Role of Risk Assessment and Co-morbidity Scores
  • 4.5 Fertility Preservation
  • 4.6 Fertility Preservation in the Paediatric Population
  • 4.6.1 Fertility Counselling
  • 4.6.2 When?
  • 4.6.3 Issues
  • 4.6.4 Who?
  • 4.6.5 Recommendations on Fertility Preservation for Girls and Young Women with Childhood Cancer
  • 4.6.5.1 Menstruating Girls
  • 4.6.5.2 All Girls Regardless of Maturational Stage
  • 4.6.6 Recommendations on Fertility Preservation for Boys and Young Men with Childhood Cancer
  • 4.6.6.1 Pubertal and Post-pubertal Males
  • 4.6.6.2 Prepubertal Boys
  • 4.6.7 Techniques
  • 4.6.8 Fertility Preservation Options for Children and Young Adults with Distinction Between Established and Experimental Options
  • 4.6.9 Sexuality in Adolescents and Young Adults
  • 4.6.10 Conclusion
  • 4.7 Transplant Workup
  • 4.8 Venous Access Devices: Principles of Placement and Care
  • 4.8.1 Vascular Access Devices
  • 4.8.2 Care and Maintenance
  • 4.8.3 Flushing and Locking
  • 4.8.4 Securement
  • 4.8.5 Occlusion
  • 4.8.6 CVAD Removal
  • 4.8.7 Pre-transplant Disease Assessment
  • 4.9 The Advocacy Role of HSCT Nurses
  • 4.10 Ethical Dilemmas
  • 4.11 Ethical Issues in Minors
  • References
  • 5: Cell Source and Apheresis
  • 5.1 Cell Source: Where Do We Get the Cells From?
  • 5.1.1 Cell Collection
  • 5.2 Mobilization of Stem Cells and Apheresis
  • 5.2.1 Cytokines
  • 5.2.2 The Role of CD34+
  • 5.2.3 Chemo-mobilization
  • 5.2.4 Alternative Mobilization Strategies
  • 5.2.5 PBSC Collection by Apheresis
  • 5.3 Vascular Access
  • 5.4 Adverse Reactions
  • 5.4.1 Citrate Toxicity
  • 5.4.2 Treatment
  • 5.4.3 Hypovolemia
  • 5.4.4 Risk Factors
  • 5.4.5 Preventative Measures.
  • 5.4.6 Clinical Manifestations
  • 5.4.7 Treatment
  • 5.4.8 Thrombocytopenia
  • 5.4.9 Treatment
  • 5.5 Patient Assessment and Preparation
  • 5.5.1 Medical Assessment
  • 5.5.2 Patient Education
  • 5.5.3 Donor Assessment and Preparation
  • 5.6 Quality in Apheresis
  • 5.6.1 Training and Competencies
  • 5.7 Cell Source and Apheresis in the Pediatric Population
  • 5.7.1 Introduction
  • 5.7.2 Apheresis in Pediatric Population
  • 5.7.3 Key Differences: Pediatric vs Adult
  • 5.7.4 Ethical Dilemmas
  • 5.7.5 Psychosocial Risks and Benefits
  • References
  • 6: Principles of Conditioning Therapy and Cell Infusion
  • 6.1 Conditioning
  • 6.2 Chemotherapy
  • 6.2.1 Combination Chemotherapy
  • 6.2.2 Cycles and Scheduling
  • 6.2.3 Modes of Administration
  • 6.2.4 Side Effects and Nursing Implications
  • 6.3 Radiotherapy
  • 6.3.1 Total Body Irradiation
  • 6.3.2 Side Effects and Nursing Implications
  • 6.4 Immunotherapy
  • 6.4.1 Cancer Immunotherapy
  • 6.4.1.1 Immune Checkpoint Blockade
  • 6.4.1.2 Immune Cell Therapy
  • 6.4.1.3 Therapeutic Antibodies
  • 6.4.1.4 Therapeutic Cancer Vaccines
  • 6.5 Paediatric Considerations
  • 6.5.1 Chemotherapy
  • 6.5.2 Total Body Irradiation
  • 6.6 Stem Cell Infusion
  • 6.6.1 Adverse Reactions
  • 6.6.2 Nursing Care: Pre-, During and Post Stem Cell Infusion
  • 6.6.2.1 Pre-infusion Assessment
  • 6.6.2.2 During Stem Cell Infusion
  • 6.6.2.3 Post Stem Cell Infusion
  • 6.6.3 JACIE Standards
  • References
  • Further Reading
  • 7: BMT Settings, Infection and Infection Control
  • 7.1 Introduction
  • 7.2 Viral Infections
  • 7.2.1 Cytomegalovirus
  • 7.2.1.1 Introduction
  • 7.2.1.2 Presentation
  • 7.2.1.3 Diagnosis
  • 7.2.1.4 Monitoring and Surveillance
  • 7.2.1.5 Treatment
  • 7.2.2 EBV
  • 7.2.2.1 Introduction
  • 7.2.2.2 Presentation and Manifestations
  • 7.2.2.3 Diagnosis
  • 7.2.2.4 Monitoring.
  • 7.2.2.5 Treatment
  • 7.2.3 HHV6
  • 7.2.3.1 Introduction
  • 7.2.3.2 Risk
  • 7.2.3.3 Presentation
  • 7.2.3.4 Diagnosis
  • 7.2.3.5 Treatment
  • 7.2.4 Pneumocystis jirovecii
  • 7.2.4.1 Introduction
  • 7.2.4.2 Risk Factors
  • 7.2.4.3 Presentation
  • 7.2.4.4 Diagnosis
  • 7.2.4.5 Treatment
  • 7.2.5 Varicella Zoster Virus
  • 7.2.5.1 Introduction
  • 7.2.5.2 Risk Factors
  • 7.2.5.3 Presentation
  • 7.2.5.4 Diagnosis
  • 7.2.5.5 Treatment
  • 7.2.6 Adenovirus
  • 7.2.6.1 Introduction
  • 7.2.6.2 Risk Factors
  • 7.2.6.3 Presentation
  • 7.2.6.4 Diagnosis
  • 7.2.6.5 Treatment
  • 7.2.7 Hepatitis B
  • 7.2.7.1 Background
  • 7.2.7.2 Clinical Features
  • 7.2.7.3 Treatment
  • 7.2.7.4 Prevention
  • 7.2.8 Hepatitis C
  • 7.2.8.1 Background
  • 7.2.8.2 Clinical Features
  • 7.2.8.3 Treatment
  • 7.2.8.4 Prevention
  • 7.2.9 Emerging Infections (Hepatitis E)
  • 7.2.9.1 Background
  • 7.2.9.2 Clinical Features
  • 7.2.9.3 HEV in Developing Countries
  • 7.2.9.4 HEV in Developed Countries
  • 7.2.9.5 Treatment
  • 7.2.9.6 Prevention
  • 7.2.10 Multiply-Resistant Bacteria: Reducing the Spread
  • 7.2.10.1 Background
  • 7.2.10.2 Contact Precautions
  • 7.2.11 Gram-Positive Bacteria
  • 7.2.11.1 Enterococci
  • 7.2.11.2 Vancomycin-Resistant Enterococci (VRE)
  • 7.2.11.3 Coagulase-Negative Staphylococcus (CNS)
  • 7.2.11.4 Staphylococcus aureus
  • 7.2.11.5 MRSA
  • 7.2.11.6 Streptococcus viridans
  • 7.2.11.7 Streptococcus pneumoniae
  • 7.2.12 Gram-Negative Bacteria
  • 7.2.12.1 Enterobacteriaceae
  • 7.2.12.2 Klebsiella pneumoniae
  • 7.2.12.3 Carbapenemase-Producing Klebsiella pneumoniae
  • 7.2.12.4 Pseudomonas aeruginosa
  • 7.2.12.5 Acinetobacter baumannii
  • 7.2.13 Clostridium difficile
  • 7.2.13.1 Background
  • 7.2.13.2 Infection Control Management
  • 7.2.13.3 Treatment
  • 7.2.13.4 Faecal Microbiota Transplant.
  • 7.3 BMT Setting, Infection and Infection Control.

Similar Items